Novel molecular insights from this study will facilitate the development of edaravone-based therapies (e.g. edaravone/GDNF combination therapy) for ALS and likely other brain disorders associated with neurodegeneration (e.g. Parkinson’s disease and stroke). This evidence concerns the gene GDNF and amyotrophic lateral sclerosis.